|
|
|
|
|
|
|
M T Wed Th F |
|
3 June, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
As the pharma industry has spent the past few years adopting AI, getting a sense of how well it's working — and how much pharma companies are spending on AI — is starting to come into focus. Drew Armstrong today has a dispatch straight from Silicon Valley on how Bristol Myers Squibb CEO Chris Boerner is trying to get a handle on AI costs. |
|
|
|
Lydia Ramsey Pflanzer |
Deputy Editor, Endpoints News
|
|
|
|
 |
|
Chris Boerner, Bristol Myers Squibb CEO |
|
|
|
by Drew Armstrong
|
PALO ALTO, CA— After giving artificial intelligence tools to thousands of employees, Bristol Myers Squibb is now working to get a handle on the... | |
|
|
|
|
|
|
by Zachary Brennan
|
Biopharma companies preparing to launch the next practice-changing blockbusters want payors to know what's coming before they ultimately land an FDA approval. The trick is... | |
|
|
|
|
|
|
by Nicole DeFeudis
|
Axsome Therapeutics has successfully delayed generic competition for its narcolepsy drug Sunosi until 2040. The company announcedon Wednesday that it has reached a
settlement... | |
|
|
|
|
|
 |
|
Jon Congleton, Mineralys Therapeutics CEO |
|
|
|
by Kyle LaHucik
|
Mineralys Therapeutics first drew attention in 2021 with a bold bet on a new type of hypertension drug called lorundrostat. It came with a tiny... | |
|
|
|
|
|
|
by Ryan Cross
|
Last month, Ascidian Therapeuticspresented the first data suggesting a new way to fix broken genes may be safe in people. Now Eli Lilly has... | |
|
|
|
|
|
|
by Kyle LaHucik
|
After losing a couple of pharma alliances in recent quarters, CytomX Therapeutics is getting a major lift from a key collaborator. Regeneron is doubling down... | |
|
|
|
|
|
